On Monday, in the course of Morning trade, Shares of Synthesis Energy Systems, Inc. (NASDAQ:SYMX), skyrocketed 68.51%, and is now trading at $1.82, hitting its highest level.
Synthesis Energy Systems, declared that it has accomplished a registered direct placement of 12,000,000 shares of its common stock for aggregate gross proceeds of $12,000,000.
T.R. Winston & Company, LLC acted as the exclusive placement agent for the offering.
Synthesis Energy Systems, Inc., a development stage energy and gasification technology company, provides various proprietary gasification technology systems and solutions to the energy and chemical industries worldwide.
Shares of Can-Fite BioPharma Ltd. (NYSEMKT:CANF), during its Monday’s current trading session surged 33.19%, and is now trading at $2.89.
Today, Can-Fite BioPharma declared favorable data from further analysis of its Phase II/III double-blind, placebo-controlled study designed to test the efficacy of CF101 in patients with moderate-to-severe plaque psoriasis.
The study comprised of 326 patients through 17 clinical centers in the U.S., Europe, and Israel with a duration of 32 weeks where the primary endpoint was after 12 weeks. On March 30, 2015, Can-Fite declared the study did not meet its primary endpoint of a statistically noteworthy improvement in the Psoriasis Area Severity Index (PASI) 75 score relative to placebo after 12 weeks of treatment. However, based on further analysis of the efficacy and safety results from the study as described below, Can-Fite intends to continue the development of CF101 for the treatment of psoriasis and has initiated work on the design of the next advanced–stage clinical trial protocol.
Further analysis of the entire study period revealed that by 32 weeks of treatment with CF101, 33% of the patients achieved PASI 75 while the mean percent of improvement in PASI score was 57%.
Most significantly, by week 32 of the study, 20% of the study patients reached PASI 90, a result demonstrating a response rate of 90% clearing of skin lesions. PASI 90 is one of the most stringent and difficult to meet clinical endpoints for measuring responses to psoriasis treatments. Moreover, the PASI 90 subset analysis further suggests a higher and noteworthy(p=0.026) CF101 response rate of 27% among patients formerly untreated with systemic psoriasis therapy contrast to patients pre-treated with systemic drugs. The Company believes this presents the opportunity that CF101 can be developed as a first-line systemic therapy for patients with moderate-severe psoriasis and for patients who do not want to be treated with the current systemic drugs due to safety issues. Presently there is no universally accepted first-line systemic therapy for patients diagnosed with psoriasis, and therefore CF101, an orally bioaccessible drug with an excellent safety profile can be positioned for this unmet need.
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and ophthalmic diseases.
Finally, iGATE Corporation (NASDAQ:IGTE), gained 3.49% Friday, hitting its highest level. after the integrated technology and operations-based solutions provider’s declaration that it will be attained by the French consulting, technology, and outsourcing services provider Capgemini (CGEMY) for $4 billion.
“IGATE strengthens Capgemini’s key businesses in application and infrastructure services in addition to BPO and engineering services. Moreover, the transaction enriches Capgemini’s portfolio with new flagship clients such as General Electric (GE) and Royal Bank of Canada (RY),” the companies said in a statement announcing the deal.
The purchase will grow Capgemini’s presence in North America, enhance the group’s competitiveness, and reinforce Capgemini’s position in the retail, manufacturing and healthcare sectors, the statement continued.
“In Capgemini, we have found a partner that will advance our ability to innovate and build industry solutions that will enhance the value proposition we bring to our clients. In addition, this powerful combination will provide exciting opportunities for our employees to expand their capabilities,” IGATE CEO Ashok Vemuri said in the statement.
iGATE Corporation, through its auxiliaries, provides information technology (IT) and IT-enabled operations offshore outsourcing solutions and services to large and medium-size organizations.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
